Pharminent

Roche’s Ocrevus racks up more positive MS data in relapsing and primary progressive forms

The positive data for Roche’s Ocrevus keep on coming. Friday, the company’s Genentech unit announced that the multiple-sclerosis fighter had significantly cut down disease activity and disability progression in patients with relapsing forms of the disease and those with the harder-to-treat, primary progressive forms. http://www.fiercepharma.com/marketing/roche-s-ocrevus-racks-up-more-positive-ms-data-relapsing-and-primary-progressive-forms

Filed under: MS